Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028053 · ClinicalTrials.gov registry record · Phase 3
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
A Phase 3 study of Mild Cognitive Impairment and Alzheimers Disease, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
- 1
- Study location
NCT01028053 is a Phase 3 study of Mild Cognitive Impairment and Alzheimers Disease that has completed, run by GE Healthcare. The registered enrollment target is 365 participants, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01028053, a Phase 3 study of Mild Cognitive Impairment and Alzheimers Disease, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Flutemetamol (18F) Injection
Study Locations (1)
New Jersey
- GE Healthcare - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028053
The ClinicalTrials.gov registry entry for NCT01028053 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (71% lower). The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Flutemetamol (18F) Injection is the first listed.
NCT01028053 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01028053 about?
NCT01028053 is a clinical study titled "Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease". This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
What is the current status of trial NCT01028053?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2009-12. Estimated completion is 2014-01.
What conditions does trial NCT01028053 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease.
What interventions are being tested in trial NCT01028053?
The interventions under investigation include: Flutemetamol (18F) Injection (DRUG).
Who is sponsoring clinical trial NCT01028053?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01028053 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
COMPLETED · Phase 3
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.